OMB157

Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Pharmaceutical Business Review
Mon, 09/2/19 - 12:24 pm
Novartis
ofatumumab
OMB157
Aubagio
clinical trials
relapsing multiple sclerosis